Dementia generic launched in UK


Mylan has launched its Rivastigmine capsules to treat dementia in Alzheimer’s patients, the first generic version of Novartis’ Exelon in the UK.

Robert J. Coury, Mylan’s Chairman and CEO, said that the drug is Mylan’s second recent first-to-market generic to be launched in the UK, following the company’s launch of Modafinil tablets, the generic version of Cephalon’s Provigil, earlier this year.

He said that the launch marks the company’s continued “commitment of providing high quality and affordable medicines to patients around the world”.

Mylan provides global generic and specialty pharmaceuticals in 150 countries and territories.